Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Patient-reported Outcomes for the Phase 3 FURLONG Study of Furmonertinib Versus Gefitinib As First-Line Therapy for Chinese Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

Yuankai Shi,Gongyan Chen,Xiang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Jie Hu, Fei Liu,Yong Jiang,Nan Ge

The Lancet Regional Health - Western Pacific（2024）

Cited 0|Views8
Key words
Non-small cell lung cancer,Epidermal growth factor receptor,Furmonertinib,AST2818,Patient-reported outcomes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined